Sickle Cell Disease Clinical Trials in Charlotte, North Carolina

6 studies are recruiting for sickle cell disease in Charlotte, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

   Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking i…

   Stage

   Phase 3

   Ages

   2 and older

   Site

   Atrium Levine Children's/Atrium Health, Charlotte, North Carolina

   Locations

   107 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT06609226 on ClinicalTrials.gov

2. A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512. This will be the first evaluation of the potential therapeutic effect of ITU512 in healthy participants …

   Stage

   Phase 1

   Ages

   12 to 55

   Site

   Levine Cancer Insitute Carolinas Healthcare System, Charlotte, North Carolina

   Locations

   10 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06546670 on ClinicalTrials.gov

3. ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

   In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond…

   Stage

   Not phased

   Ages

   Any age

   Site

   St. Jude Affiliate Clinic at Novant Health Hemby Children's Hospital, Charlotte, North Carolina

   Locations

   76 in total

   Run by

   American Thrombosis and Hemostasis Network

   See if you can join NCT04398628 on ClinicalTrials.gov

4. Sickle Cell Clinical Research and Intervention Program

   Despite the important work of previous sickle cell disease (SCD) cohort studies, there remain many understudied areas that require investigation. An important knowledge deficit is the slow but progressive process of chronic end-organ dysfunction. The majority of organ dysfunction becomes apparent i…

   Stage

   Not phased

   Ages

   Any age

   Site

   Novant Health Hemby Children's Hospital, Charlotte, North Carolina

   Locations

   6 in total

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT02098863 on ClinicalTrials.gov

5. Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

   This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) using CTX001.

   Stage

   Phase 3

   Ages

   12 to 35

   Site

   Levine Children's Hospital - Hematology, Charlotte, North Carolina

   Locations

   6 in total

   Run by

   Vertex Pharmaceuticals Incorporated

   See if you can join NCT05477563 on ClinicalTrials.gov

6. Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

   This multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can decrease the toxicity of transplant while achieving a high cure rate …

   Stage

   Phase 2

   Ages

   2 to 25

   Site

   Levine Children's Hospital, Charlotte, North Carolina

   Locations

   7 in total

   Run by

   Robert Nickel

   See if you can join NCT03587272 on ClinicalTrials.gov